Full Title: Addressing Pharma’s R&D Productivity Crisis: Technological and Strategic Initiatives to Improve Core Drug Discovery Capabilities
FREE BONUS REPORT(S): When you buy below report, you may pick 3 additional cancer reports for free from this list
(Value: 7,400 USD)
Introduction External pressures make it difficult to maintain the growth enjoyed by the pharmaceutical industry over the past two decades. Expenditure on R&D is increasing but is not accompanied by corresponding growth in the number of new drugs reaching the market. Companies must fundamentally review R&D business models and exploit new strategies for re-establishing core drug discovery expertise Scope - Analysis of the R&D challenges faced by leading pharmaceutical companies and critical review of company initiatives to restore productivity
- Examines technological opportunities including genomics-oriented target validation, rationalized HTS and GRID computing
- Drug discovery database - more than 450 drug discovery deals (Sep 02 - Mar 04) between more than 200 capability providers and 140 pharma companies
- Clinical pipeline database - 1,377 projects from the pipelines of 200 companies
Highlights To restore shareholder and stakeholder confidence companies must deliver improved productivity and innovation they must fundamentally review R&D business models and exploit new strategies for improving core drug discovery expertise. Investment in technology in the 1990s has not been followed by an increase in R&D productivity. Recognizing that no single technology offers a panacea for drug discovery, the industry must now improve the way in which it evaluates new technologies and capabilities. The industry can expect the new drug discovery paradigm to be based upon the integration of fields, such as, genomics and proteomics, structural biology, chemistry, physiology, pharmacology and population biology, alongside the integration of the clinic and the laboratory. Reasons to Purchase - Review the current R&D pipelines and recent drug discovery deal activity of leading the pharmaceutical companies
- Analyze competitor deal-making activity and identify emerging trends in drug discovery by examining Datamonitor’s drug discovery deal database
- Identify potential drug discovery partners and new opportunities for accessing drug discovery capability
Pages: 208 Table of Contents Download TOC in PDF
|
